Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd.

Ishizaki Co., Ltd.

Astrazeneca Aktiebolag

Futoshi Hasegawa

Hitoshi Ban

Daisuke Kikuchi

Seiji Hori

Hirotaka Kurebayashi

Daisuke Urabe

Manabu Kusagi

Shingo Tojo

Miki Hashizume

Kazuhiko Kojima

Nobuyuki Ishizaki

Takeshi Ouchi

Yusuke Yoshida

Yosuke Takanashi

Eiji Hara

Yasushi Hiramine

Kazuhiro Ota

Kohei Mizutani

Masayo Fujiwara

The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R, R, Rm, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.

Carboxylic acid compounds

The check valve () is of straight pipe joint type and oblique lift type. It includes: a valve seat (); a moving body () capable of linearly reciprocating between a closed state where it is in close contact with the valve seat and an open state where it is separated from the valve seat; a primary flow path (inflow path ()) on an upstream side of the moving body; and a secondary flow path (outflow path ()) on a downstream side of the moving body. The moving body includes a valve body () and a valve shaft () extending from the valve body. The valve seat supporting the valve body is formed to straddle the center line (CL) of the connection flow path that linearly extends including the primary flow path (inflow path) and the secondary flow path (outflow path) in a cross section including the center line thereon.

Check valve

The present invention provides a 1,4-disubstituted imidazole derivative of formula (1') wherein ring Qis optionally-substituted Caryl group, etc.; Rand Rare independently hydrogen atom, etc.; Wis optionally-substituted Calkylene group; Wis &#x2014;NRC(O)&#x2014; wherein Ris hydrogen atom or Calkyl group, etc.; ring Qis 5- to 10-membered heteroaryl group, etc.; Wis optionally-substituted Calkylene group, etc.; n is 1, 2, 3, 4, or 5; Ris independently halogen atom, optionally-substituted Calkyl group, etc.; Ris hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent. 

1,4-disubstituted imidazole derivative

The present invention provides a compound of formula (1) or a salt thereof wherein ring Qis optionally-substituted Caryl, etc.; Rand Rare independently hydrogen atom, etc.; Wis Calkylene which may be optionally substituted with 1 to 3 fluorine atoms or Ccycloalkyl; Wis &#x2014;NRC(O)&#x2014;, etc. wherein Ris hydrogen atom or Calkyl; ring Qis optionally-substituted Caryl, etc., which has an inhibitory effect on the sphere-forming ability of cancer cells and is useful an agent for removing iPS cells. 

Agent for removing undifferentiated iPS cells

A reciprocating body () has valve element () including deflecting surface (), valve shaft () guided by guide cylinder (), and packing () having an annular shape circularly brought into close contact with valve seat () in a state where the reciprocating body () is in a closed position. The valve element () includes large diameter portion (), and small diameter portion () and deflecting portion (). The large diameter portion () has flange surface () supporting the packing () in a state where the packing () is exposed to the primary flow passage side. The flange surface () is formed such that the flange surface () is allowed to come into contact with the valve seat () via the packing (). Recess () is formed on the outer periphery of the small diameter portion (), and a portion of the packing () is fitted in the recess ().

Check valve and reciprocating body for check valve

The present invention provides a bicyclic heterocyclic amide derivative of formula (1) wherein ring Qis optionally-substituted Caryl group, etc.; Rand Rare independently hydrogen atom, etc.; Wis optionally-substituted Calkylene group; Wis &#x2014;NRC(O)&#x2014;, etc. wherein Ris hydrogen atom or Calkyl group; Cyis the following group of formula (11), etc.; ring Qis optionally-substituted benzene ring, etc.; n and m are independently 0, 1 or 2, provided that n and m are not simultaneously 0; X is NR, etc.; Ris hydrogen atom, etc.; p is 1, 2, 3, 4 or 5; Ris, independently when two or more exist, hydrogen atom, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming ability of cancer cells and are useful as an orally-available anti-tumor agent. 

Bicyclic heterocyclic amide derivative

The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: (I) wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer. 

Growing community of inventors

Osaka, Japan

Futoshi Hasegawa